Recruiting

European registry tracking fatty liver disease and related health conditions

Plain-English translation of NCT04442334 on ClinicalTrials.gov ↗ · Source last updated January 2023 · Translation generated June 2026 · How we translate trials

What is this trial?

The European NAFLD Registry is a large observational study collecting medical data and biological samples (blood, liver tissue, urine, and stool) from patients with non-alcoholic fatty liver disease (NAFLD) across Europe. Researchers will use this information to understand how the disease develops and to identify new biomarkers—biological signals that could help diagnose and monitor the condition. The study aims to enroll 10,000 patients and involves collaboration between leading universities across Europe.

Non-alcoholic fatty liver disease affects many people, especially those with obesity, diabetes, and related metabolic conditions, but doctors still lack reliable ways to detect and monitor it early. This registry was created to gather comprehensive information and samples that will help researchers discover better diagnostic tools and understand what factors influence how the disease progresses.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with fatty liver disease confirmed by biopsy, imaging, or blood tests combined with metabolic risk factors
you drink less than 21 units of alcohol per week (if male) or 14 units per week (if female), with no history of heavy drinking in the past 5 years
you do not have Type 1 diabetes or other forms of chronic liver disease
you are able to give informed consent and speak English or have access to an interpreter

You likely don't qualify if…

you have drunk more than 21 units of alcohol per week (if male) or 14 units per week (if female) in the past 6 months or have a history of sustained heavy drinking
you have Type 1 diabetes or other chronic liver diseases besides fatty liver disease
you are currently taking medications known to cause liver fat buildup (such as long-term corticosteroids, amiodarone, or methotrexate)
you have recently started or changed doses of vitamin E supplements or similar compounds (within 3 months)
you cannot safely undergo a liver biopsy or cannot understand or consent to the study in English

What participation looks like

You will visit hepatology or diabetology clinics at participating centers across Europe, where doctors will review your medical history and current health. You will have standard blood tests, imaging (such as ultrasound or MRI), and possibly a liver biopsy if medically appropriate. You will also donate biological samples including blood, and possibly urine and stool samples, which researchers will analyze to understand your disease and develop better diagnostic tools. The study collects information over time, so you may be contacted for follow-up visits to track how your condition changes.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(37 sites)

Belgium

Universitair Ziekenhuis Antwerpen, Antwerp

Finland

Helsinki University Hospital, Helsinki

France

Le Centre de Recherche Clinique (CRC) du CHU d'Angers, Angers

Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière, Paris

Germany

UNIVERSITÄTSKLINIKUM der RWTH Aachen, Aachen